Andere Sprachen Senti Biosciences, Inc.

Aktien

SNTI

US81726A1007

SNTI

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:20:47 16.05.2024			% 5 Tage	% 1. Jan.
0,373 ^USD	-1,32 %		-5,43 %	-42,73 %

09.05.	Senti Biosciences, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
30.04.	Senti Biosciences, Inc. gibt die Veröffentlichung der präklinischen Daten von SENTI-202 bekannt, die das Potenzial der logikgesteuerten CAR-NK-Zelltherapie für die Behandlung der akuten myeloischen Leukämie (AML) belegen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	13.05.
Senti Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights	09.05.
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)	30.04.
Senti Biosciences, Inc. Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia	30.04.
Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Chief Financial Officer, Effective May 3, 2024	26.04.
Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Treasurer and Head of Corporate Development, Effective May 3, 2024	26.04.
Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
Earnings Flash (SNTI) SENTI BIOSCIENCES Reports 2023 Revenue $2.6M	21.03.
Senti Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21.03.
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights	21.03.
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program	05.01.
Spark Therapeutics, Inc. Announces Workforce Reduction	05.01.
Top Premarket Gainers	22.12.
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22.12.
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22.12.
Senti Biosciences, Inc. Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22.12.
Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
Earnings Flash (SNTI) SENTI BIOSCIENCES Posts Q3 Revenue $338,000	13.11.
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates	13.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Senti Biosciences, Inc.

Aktien

SNTI

US81726A1007

SNTI

Andere Sprachen

Filter